Dasanix 20 mg (Tablet)

Unit Price: ৳ 80.00 (3 x 10: ৳ 2,400.00)
Strip Price: ৳ 800.00

Medicine Details

Category Details
Generic Dasatinib
Company Beacon pharmaceuticals plc
Also available as
Dasanix 100 mg tablet Dasanix 50 mg tablet

Indications

  • Treatment for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
  • Treatment for chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib
  • Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
  • Treatment for pediatric patients 1 year of age and older with Ph+ CML in chronic phase
  • Treatment for newly diagnosed Ph+ ALL in combination with chemotherapy

Pharmacology

  • Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
  • Active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
  • Predicted binding to multiple conformations of the ABL kinase
  • Active against leukemic cell lines overexpressing BCR-ABL
  • Absorption between 0.5 to 6 hours following oral administration
  • Inhibition of the growth of CML and ALL cell lines overexpressing BCR-ABL
  • Primary metabolism by CYP3A4
  • Approximately 96% binding to human plasma proteins in vitro
  • Eliminated primarily via the feces
  • Volume of distribution is 2505 (CV% 93%)

Dosage & Administration

  • Starting dosage of 100 mg for chronic phase CML in adults
  • Starting dosage of 140 mg for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults
  • Oral administration once daily
  • Dosage based on body weight for pediatric patients
  • Tablets should not be crushed, cut, or chewed

Interaction

  • Coadministration with strong CYP3A inhibitors may increase Dasanix concentrations
  • Coadministration with strong CYP3A inducers may decrease Dasanix concentrations
  • Coadministration with gastric acid reducing agents may decrease Dasanix concentrations

Contraindications

  • Known hypersensitivity to Dasatinib or any component of the formulation

Side Effects

  • Myelosuppression
  • Bleeding-related events
  • Fluid retention
  • Cardiovascular events
  • Pulmonary arterial hypertension
  • QT prolongation
  • Severe dermatologic reactions
  • Tumor lysis syndrome
  • Effects on growth and development in pediatric patients

Pregnancy & Lactation

  • Potential fetal harm when administered to a pregnant woman
  • Advice for females of reproductive potential to avoid pregnancy during treatment
  • Not recommended for breastfeeding

Precautions & Warnings

  • Severe thrombocytopenia, neutropenia, and anemia
  • Risk of serious and fatal bleeding
  • Potential for fluid retention
  • Risk of cardiac dysfunction
  • Risk of pulmonary arterial hypertension
  • Risk of QT prolongation
  • Potential severe mucocutaneous dermatologic reactions
  • Risk of tumor lysis syndrome

Overdose Effects

  • Limited experience with overdose
  • Reported severe myelosuppression and bleeding in isolated cases

Therapeutic Class

  • Targeted Cancer Therapy

Storage Conditions

  • Store below 30°C in a dry place
  • Protect from light
  • Keep out of the reach of children

Related Brands